



Claims

I claim:

1. A statin analog that inhibits HMG-CoA reductase and has at least one characteristic chosen from the group consisting of:
  - a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
  - b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
  - c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
  - d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
  - e. the primary metabolites are soluble in water at physiological pH;
  - f. the primary metabolites have negligible inhibitory activity at the  $IK_R$  (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
  - g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
  - h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone.


2. The inhibitor of HMG-CoA reductase, according to claim 1, having a structure selected from the group consisting of:





and salts thereof.

3. The compound, according to claim 1, wherein said compound has a structure selected from the group consisting of:



and salts thereof.





5. A pharmaceutical composition comprising a statin analog that inhibits HMG-CoA reductase and has at least one characteristic chosen from the group consisting of:

- a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
- b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
- c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
- d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
- e. the primary metabolites are soluble in water at physiological pH;
- f. the primary metabolites have negligible inhibitory activity at the  $IK_R$  (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
- g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
- h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone;

wherein said composition further comprises a pharmaceutical carrier.

6. The pharmaceutical composition, according to claim 5, wherein said compound has a structure selected from the group consisting of:






and salts thereof.




7. The pharmaceutical composition, according to claim 5, wherein said compound has a structure selected from the group consisting of:



and salts thereof.

8. The composition, according to claim 5, wherein said compound has a structure selected from the group consisting of:




and salts thereof.

9. A method for inhibiting HMG-CoA reductase in an individual in need of such treatment wherein said method comprises administering to said individual a pharmaceutical composition comprising a statin analog that inhibits HMG-CoA reductase and has at least one characteristic chosen from the group consisting of:


- a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
- b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
- c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
- d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
- e. the primary metabolites are soluble in water at physiological pH;
- f. the primary metabolites have negligible inhibitory activity at the I<sub>KR</sub> (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
- g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
- h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone.

[illegible]




S:\SH-APPS\ARYX-116XC1.doc/DNB/la

11. The method, according to claim 9, wherein said compound has a structure selected from the group consisting of:



and salts thereof.

12. The method, according to claim 9, wherein said compound has a structure selected from the group consisting of:



13. The method, according to claim 9, wherein the individual is a human.

14. The method, according to claim 9, wherein said method is used to lower cholesterol levels.